110
Participants
Start Date
July 20, 2020
Primary Completion Date
April 1, 2026
Study Completion Date
April 1, 2029
Sacituzumab Govitecan
Intravenous Infusion
Pembrolizumab
Intravenous Infusion
RECRUITING
University of Pennsylvania-Abramson Cancer Center, Philadelphia
RECRUITING
The University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Sarah Cannon Research Institute, Chattanooga
RECRUITING
Ohio State University Medical Center, Columbus
RECRUITING
University of Chicago Medical Center, Chicago
RECRUITING
Stamford Hospital, Stamford
RECRUITING
Eastern Maine Medical Center, Brewer
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
DFCI @ Foxborough, Foxborough
RECRUITING
DFCI @ Milford Regional Hospital, Milford
RECRUITING
DF/BWCC in Clinical Affiliation with South Shore Hospital, South Weymouth
Collaborators (1)
Gilead Sciences
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Dana-Farber Cancer Institute
OTHER